- Home
- ACNB vs ARVN Comparison
ACNB vs ARVN Comparison
Compare ACNB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACNB
- ARVN
- Stock Information
- Founded
- ACNB 1857
- ARVN 2015
- Country
- ACNB United States
- ARVN United States
- Employees
- ACNB N/A
- ARVN N/A
- Industry
- ACNB Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ACNB Finance
- ARVN Health Care
- Exchange
- ACNB Nasdaq
- ARVN Nasdaq
- Market Cap
- ACNB 468.6M
- ARVN 456.2M
- IPO Year
- ACNB N/A
- ARVN 2018
- Fundamental
- Price
- ACNB $45.48
- ARVN $7.46
- Analyst Decision
- ACNB Strong Buy
- ARVN Buy
- Analyst Count
- ACNB 3
- ARVN 22
- Target Price
- ACNB $50.00
- ARVN $20.02
- AVG Volume (30 Days)
- ACNB 19.1K
- ARVN 1.3M
- Earning Date
- ACNB 10-23-2025
- ARVN 10-29-2025
- Dividend Yield
- ACNB 3.01%
- ARVN N/A
- EPS Growth
- ACNB N/A
- ARVN N/A
- EPS
- ACNB 2.69
- ARVN N/A
- Revenue
- ACNB $123,053,000.00
- ARVN $372,800,000.00
- Revenue This Year
- ACNB $40.40
- ARVN $1.61
- Revenue Next Year
- ACNB $4.84
- ARVN N/A
- P/E Ratio
- ACNB $16.79
- ARVN N/A
- Revenue Growth
- ACNB 15.31
- ARVN 299.57
- 52 Week Low
- ACNB $35.70
- ARVN $5.90
- 52 Week High
- ACNB $50.72
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- ACNB 55.73
- ARVN 46.40
- Support Level
- ACNB $44.12
- ARVN $7.58
- Resistance Level
- ACNB $46.13
- ARVN $7.89
- Average True Range (ATR)
- ACNB 0.83
- ARVN 0.39
- MACD
- ACNB -0.09
- ARVN -0.04
- Stochastic Oscillator
- ACNB 71.77
- ARVN 13.43
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.